HomeComparePPCBD vs GBDC

PPCBD vs GBDC: Dividend Comparison 2026

PPCBD yields 35.21% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.60M in total portfolio value· pulled ahead in Year 5
10 years
PPCBD
PPCBD
● Live price
35.21%
Share price
$5.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.0K
Annual income
$27,022.57
Full PPCBD calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — PPCBD vs GBDC

📍 GBDC pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPPCBDGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PPCBD + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PPCBD pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PPCBD
Annual income on $10K today (after 15% tax)
$2,992.96/yr
After 10yr DRIP, annual income (after tax)
$22,969.18/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,907,904.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PPCBD + GBDC for your $10,000?

PPCBD: 50%GBDC: 50%
100% GBDC50/50100% PPCBD
Portfolio after 10yr
$10.48M
Annual income
$8,208,142.98/yr
Blended yield
78.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

PPCBD
No analyst data
Altman Z
-18.6
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PPCBD buys
0
GBDC buys
0
No recent congressional trades found for PPCBD or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPPCBDGBDC
Forward yield35.21%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$178.0K$20.78M
Annual income after 10y$27,022.57$16,389,263.41
Total dividends collected$128.7K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: PPCBD vs GBDC ($10,000, DRIP)

YearPPCBD PortfolioPPCBD Income/yrGBDC PortfolioGBDC Income/yrGap
1$14,221$3,521.13$12,490$1,790.28+$1.7KPPCBD
2$19,896$4,679.85$16,522$3,157.73+$3.4KPPCBD
3$27,408$6,119.13$23,578$5,898.68+$3.8KPPCBD
4$37,205$7,877.95$37,115$11,886.75+$90.00PPCBD
5← crossover$49,803$9,994.16$66,136$26,423.57$16.3KGBDC
6$65,793$12,503.21$137,257$66,491.44$71.5KGBDC
7$85,835$15,436.81$341,734$194,868.54$255.9KGBDC
8$110,665$18,821.76$1,050,788$685,133.02$940.1KGBDC
9$141,091$22,678.96$4,099,314$2,974,971.01$3.96MGBDC
10$177,990$27,022.57$20,775,530$16,389,263.41$20.60MGBDC

PPCBD vs GBDC: Complete Analysis 2026

PPCBDStock

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Full PPCBD Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this PPCBD vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PPCBD vs SCHDPPCBD vs JEPIPPCBD vs OPPCBD vs KOPPCBD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.